Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis.
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Teriparatide (Primary) ; Raloxifene
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms EUROFORS
- Sponsors Eli Lilly and Company
- 04 Jun 2009 Results from substudy 2 have been reported in the Journal of Bone and Mineral Research.
- 04 Jun 2009 Primary endpoint 'Lumbar spine bone mineral density' has been met.
- 27 Jul 2006 Status change